Eli Lilly Agrees to Acquire In Vivo CAR‑T Developer Kelonia for $7 Billion
Mega Deal to Secure an In Vivo CAR‑T Platform
Eli Lilly and Company (LLY) has reached a definitive agreement to acquire next‑generation gene‑therapy developer Kelonia Therapeutics for a total consideration of $7 billion. The transaction consists of a non‑refundable upfront payment of $3.25 billion and $3.75 billion in milestones, underscoring a heavyweight bet by big pharma. Conventional ex vivo CAR‑T therapies require extraction of patient cells, lengthy manufacturing, and consequently high costs and long wait times. Kelonia’s lentiviral‑vector‑based in vivo gene‑positioning control system (iGPS®) platform creates therapeutic T cells directly inside the patient, a technology touted as capable of eliminating the time‑ and cost‑barriers of current approaches.
Potent Impact Demonstrated in Phase 1 Clinical Data
Kelonia’s lead pipeline, the BCMA‑targeted in vivo CAR‑T candidate KLN‑1010, is currently in a Phase 1 trial in Australia. Preliminary human data presented at the American Society of Hematology (ASH) meeting in November 2025 showed that all three patients with relapsed/refractory multiple myeloma achieved MRD‑negative status at both the 1‑month and 3‑month assessments, indicating strong efficacy. Despite being in an ultra‑early clinical stage, the compelling data prompted Eli Lilly to move forward decisively with the acquisition. The platform also holds promise for expanding indications beyond multiple myeloma into autoimmune diseases, adding substantial commercial upside.
Rarity of Target Assets and Competitive M&A Landscape
The biotech market is experiencing a defensive M&A surge as large pharma seeks to lock in the next wave of cell‑therapy assets. Eli Lilly’s recent $2.4 billion acquisition of Orna, AbbVie’s (ABBV) $2.1 billion purchase of Capsita, and Bristol Myers Squibb’s (BMY) $1.5 billion deal for Orbital illustrate this trend. According to PitchBook analyst Ben Zercher, truly viable in vivo CAR‑T biotech companies are extremely scarce. Consequently, the strategic value of the few remaining targets—such as Umoja Biopharma, for which AbbVie holds a $1.4 billion option, and China’s Starna Therapeutics—has risen sharply.
Clinical Data as Commercial Proof Amid a Funding Winter
Kelonia weathered a difficult period after early‑stage venture capital backing from Venrock in 2020, nearly exhausting its cash during the 2022 biotech funding slowdown. The company rebounded with an $800 million technology‑transfer agreement and bridge loan from Astellas Pharma in 2024, enabling entry into the Australian trial, followed by a partnership with Johnson & Johnson (JNJ) in 2025 and the successful ASH data release. This deal demonstrates that, even in a funding‑constrained environment, validated clinical data remain the sole catalyst for a biotech’s survival and astronomical valuation.
Eli Lilly’s acquisition of Kelonia represents a mega‑deal that validates the commercial dominance of in vivo CAR‑T technology in the roughly $27 billion multiple myeloma market and the emerging next‑generation autoimmune space as of 2026. By securing Kelonia’s BCMA‑targeted candidate KLN‑1010, which has already shown human efficacy in Phase 1, the deal accelerates a generational shift away from the ex vivo CAR‑T market currently shared by Gilead and Legend Biotech. In the short term, the strategic value of the few remaining, validated in vivo CAR‑T assets such as Umoja and Starna is expected to surge, intensifying competition among big pharma for the remaining targets. Over the medium to long term, the adoption of an “off‑the‑shelf” approach that overcomes the high‑cost and long‑manufacturing timelines of traditional cell therapies will drive greater capital efficiency and a paradigm shift across the cell‑ and gene‑therapy industry.